CellSource Co

CellSource Co Days Payable Outstanding

The Days Payable Outstanding (DPO) of CellSource Co (4880.T) as of Nov 5, 2026 is 13.91. In the previous year, Days Payable Outstanding (DPO) was 17.05 — a change of -18.40% (lower).

Days Payable Outstanding

13.91

YoY

-18.40%

Last updated:

Days Payable Outstanding (DPO) of CellSource Co is 2025 13.91 . Days Payable Outstanding (DPO) of CellSource Co was 2024 17.05 . It decreases by -18.40% lower compared to the previous year.

The CellSource Co Days Payable Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Days Payable Outstanding
Date
Days Payable Outstanding
Jan 1, 2018
33.83 JPY
Jan 1, 2019
11.49 JPY
Jan 1, 2020
18.04 JPY
Jan 1, 2021
17.42 JPY
Jan 1, 2022
32.75 JPY
Jan 1, 2023
20.39 JPY
Jan 1, 2024
17.05 JPY
Jan 1, 2025
13.91 JPY
The CellSource Co Days Payable Outstanding history
YEARDays Payable OutstandingYoY
13.91-18.40%
17.05-16.38%
20.39-37.74%
32.75+87.97%
17.42-3.42%
18.04+56.98%
11.49-66.03%
33.83+165.73%
12.73—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CellSource Co Stock analysis

What does CellSource Co do? CellSource Co., Ltd. generates revenue through its Regenerative Medicine Related business segment, which provides contracted services for processing tissues and cells from fat and blood to medical institutions, along with support services for regenerative medicine laws and regulations related to safety assurance. The company also sells medical equipment within this segment. The Consumer business segment focuses on selling cosmetics and facial products directly to general consumers. Both segments operate under the company's brand without additional brand names mentioned in the description. The Regenerative Medicine Related business segment targets medical institutions and regulatory compliance support for regenerative medicine safety, while the Consumer business segment serves general consumers seeking cosmetics and facial care products. The company's products include processed tissue and cell services, regulatory support, medical equipment, and consumer skincare items, all sold under the CellSource brand. CellSource Co., Ltd. employs 109 full-time employees to manage its two business segments, with the Regenerative Medicine Related segment handling medical services and equipment sales, and the Consumer segment focusing on direct-to-consumer product sales. The company's revenue streams are derived from these two distinct operational areas without any additional external partnerships or third-party brands. CellSource Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CellSource Co stock

Days Payable Outstanding (DPO) of CellSource Co is 13.91 in 2025.

Days Payable Outstanding (DPO) of CellSource Co changed from 17.05 to 13.91, representing a -18.40% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Days Payable Outstanding (DPO) CellSource Co since 2006 – with annual values, charts, and detailed analysis.

DPO measures the average number of days a company takes to pay its suppliers. Higher DPO can improve cash flow but may strain supplier relationships.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Days Payable Outstanding (DPO)'s CellSource Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Days Payable Outstanding (DPO)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Days Payable Outstanding (DPO).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — CellSource Co

All Key Metrics — CellSource Co